Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
The review compares individual case safety reports (ICSRs) for hydroxychloroquine, favipiravir, and the lopinavir/ ritonavir combination registered in the VigiBase global database during 6 months in 2019 and the same period in 2020 which coincides with the global “first wave”. The aim of the study w...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2020-09-01
|
| Col·lecció: | Регуляторные исследования и экспертиза лекарственных средств |
| Matèries: | |
| Accés en línia: | https://www.vedomostincesmp.ru/jour/article/view/334 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|